Cancer. It’s not just a pervasive disease -- it’s a pervasive life norm. Athletes wear pink ribbons for breast cancer awareness. Children and grandparents alike walk in Relays for Life. Cancer is one of the few unifying forces in this divided world, because at the end of the day, we are all impacted by it, and we all feel the same - let’s beat it.

Right now, Tumor Treating Fields (TTF) is a therapy found very successful in helping us win that battle against solid tumor cancer However, that is only true for when patients have one solid tumor cancer. When a late-stage cancer patients presents with metastatic disease in two or more locations on the body at once, TTF cannot treat both of those areas at once. The patient must make the painful decision of which cancer to treat...and which cancer to let grow.

That’s where Lifebridge 10,000 comes into play and as the anti-cancer, pro-TTF white knight. Inspired by Laurie, CEO Peter Travers’ wife, Lifebridge 10,000 has built and successfully tested a patent-pending prototype that would allow TTF to treat multiple cancers at once in that type of situation. Laurie was forced to make the choice of which cancer to fight and which cancer to leave, and Peter wants to make sure that cancer patients using TTF will not have to make that decision ever again.

A percentage of profits will be given to patients who cannot afford treatment. LifeBridge will also sell their therapy on a sliding scale, with those less fortunate given significant discounts. Sadly, the market for this device is strong, and the demand is high. WHO predicts a 65% growth in the number of new cancer patients over the next 15 years, and pharmaceutical companies are jumping on board with TTF - Pfizer, Johnson and Johnson, and other firms have raised over $250,000,000 to make TTF the accepted 4th modality for cancer treatment.

The bottom line is that investing in Lifebridge 10,000 could mean that you’ll get a doubly high return - your profit means that you’re helping to beat cancer.